Shire’s SHP647 bags another orphan badge
US regulators have awarded orphan drug status to Shire’s investigational therapy, SHP647, for the treatment of paediatric patients with moderately to severely active Crohn’s disease.
Read More
Tag: SHP647
Orphan status for Shire’s experimental UC drug
US regulators have granted Shire’s investigational therapy SHP647 orphan status for the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
